Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Abstract Background The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in preclinical and early AD (mild cognit...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri, Jeffrey Cummings
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2022-04-01
Edice:	Alzheimer’s Research & Therapy
Témata:	Alzheimer’s disease Clinical trials Clinical meaningfulness Meaningful benefit Biomarkers Preclinical
On-line přístup:	https://doi.org/10.1186/s13195-022-00984-y
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!